Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DALLAS, TX – August 14, 2015 – Innovastics, LLC is pleased to announce the successful exclusive license of the OEA (Oleoylethanolamide), a fatty acid metabolite that regulates appetite and healthy body fat.
The OEA is one of the mediators of lipid metabolism, insulin secretion, energy expenditure and gastrointestinal motility based upon its mechanism of action and its main target receptors - the PPAR-a (peroxisome proliferator activated-receptor alpha) and the GPR119. Additional anti-inflammatory and neuroprotective actions of OEA have been suggested.
“We are very excited about the license of the OEA. The research findings to date suggest that the OEA has the potential to improve the quality of life Americans by maintaining healthy body fat” says Shashi Marulappa, the founder & CEO of Innovastics.
Innovastics acquired full rights to develop the OEA for all human and veterinary uses. The company intends to develop OEA as enteric coated dietary supplement tablet and beverages for healthy appetite and lean muscle mass.
About Innovastics, LLC:
Innovastics is a privately held limited liability company (LLC) based in Plano (Dallas-Fort worth Metroplex), TX. Innovastics is engaged in the development of novel healthcare products based on biotech and life science inventions.
For more information about Innovastics, please visit us at www.innovastics.com or contact us by email at info@innovastics.com.
Help employers find you! Check out all the jobs and post your resume.
DALLAS, TX – August 14, 2015 – Innovastics, LLC is pleased to announce the successful exclusive license of the OEA (Oleoylethanolamide), a fatty acid metabolite that regulates appetite and healthy body fat.
The OEA is one of the mediators of lipid metabolism, insulin secretion, energy expenditure and gastrointestinal motility based upon its mechanism of action and its main target receptors - the PPAR-a (peroxisome proliferator activated-receptor alpha) and the GPR119. Additional anti-inflammatory and neuroprotective actions of OEA have been suggested.
“We are very excited about the license of the OEA. The research findings to date suggest that the OEA has the potential to improve the quality of life Americans by maintaining healthy body fat” says Shashi Marulappa, the founder & CEO of Innovastics.
Innovastics acquired full rights to develop the OEA for all human and veterinary uses. The company intends to develop OEA as enteric coated dietary supplement tablet and beverages for healthy appetite and lean muscle mass.
About Innovastics, LLC:
Innovastics is a privately held limited liability company (LLC) based in Plano (Dallas-Fort worth Metroplex), TX. Innovastics is engaged in the development of novel healthcare products based on biotech and life science inventions.
For more information about Innovastics, please visit us at www.innovastics.com or contact us by email at info@innovastics.com.
Help employers find you! Check out all the jobs and post your resume.
